RECRUITINGINTERVENTIONAL

Hydroxychloroquine in Type 2 Diabetes During Pregnancy

Hydroxychloroquine as an Adjunct Therapy in the Management of Type 2 Diabetes in Pregnancy: A Randomised Controlled Trial

About This Trial

The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus. The main questions it aims to answer are: * Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy? * Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment

Who May Be Eligible (Plain English)

Who May Qualify: - Singleton - Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus Who Should NOT Join This Trial: - autoimmune conditions (where your immune system attacks your own body) such as Systemic Lupus Erythematosus or rheumatic disease - chronic kidney disease - fetal anomaly - women on steroid therapy - diabetic retinopathy - known thalassaemia or thalassaemia carrier Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Singleton * Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus Exclusion Criteria: * autoimmune disease such as Systemic Lupus Erythematosus or rheumatic disease * chronic kidney disease * fetal anomaly * women on steroid therapy * diabetic retinopathy * known thalassaemia or thalassaemia carrier

Treatments Being Tested

DRUG

Hydroxychloroquine Oral Tablet

200mg daily

Locations (1)

Antenatal clinic, UKM Medical Centre

Cheras, Kuala Lumpur, Malaysia